WO2009025159A1 - Detection and treatment of schizophrenia - Google Patents
Detection and treatment of schizophrenia Download PDFInfo
- Publication number
- WO2009025159A1 WO2009025159A1 PCT/JP2008/063803 JP2008063803W WO2009025159A1 WO 2009025159 A1 WO2009025159 A1 WO 2009025159A1 JP 2008063803 W JP2008063803 W JP 2008063803W WO 2009025159 A1 WO2009025159 A1 WO 2009025159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- schizophrenia
- disclosed
- detection
- treatment
- glyoxalase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a schizophrenia detection method. Also disclosed is a schizophrenia detection reagent or apparatus for use in the method. Further disclosed is a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia comprises a carbonyl scavenger or an inhibitor of the production of a protein-modified product of a carbonyl compound as an active ingredient. The schizophrenia detection method is achieved by the step of measuring at least one item selected from the group consisting of the following items (1) to (4) in a subject: (1) the genetic abnormality of glyoxalase-I gene; (2) the expression level or activity of glyoxalase-I in a biological sample; (3) the quantity of a carbonyl compound or a protein-modified product thereof; and (4) and the quantity of pyridoxal in a biological sample.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL08792016T PL2189537T3 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
SI200831305T SI2189537T1 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
EP08792016.1A EP2189537B1 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
ES08792016.1T ES2515168T3 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
DK08792016.1T DK2189537T3 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
US12/674,018 US8809329B2 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
US14/325,808 US20140335517A1 (en) | 2007-08-20 | 2014-07-08 | Detection and treatment of schizophrenia |
HRP20140993AT HRP20140993T1 (en) | 2007-08-20 | 2014-10-16 | Detection and treatment of schizophrenia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-214047 | 2007-08-20 | ||
JP2007214047A JP5288365B2 (en) | 2007-07-17 | 2007-08-20 | Examination and treatment of schizophrenia |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/674,018 A-371-Of-International US8809329B2 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
US14/325,808 Division US20140335517A1 (en) | 2007-08-20 | 2014-07-08 | Detection and treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009025159A1 true WO2009025159A1 (en) | 2009-02-26 |
Family
ID=40378067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/063803 WO2009025159A1 (en) | 2007-08-20 | 2008-07-31 | Detection and treatment of schizophrenia |
Country Status (11)
Country | Link |
---|---|
US (2) | US8809329B2 (en) |
EP (2) | EP2662453A3 (en) |
JP (1) | JP5288365B2 (en) |
CY (1) | CY1115640T1 (en) |
DK (1) | DK2189537T3 (en) |
ES (1) | ES2515168T3 (en) |
HR (1) | HRP20140993T1 (en) |
PL (1) | PL2189537T3 (en) |
PT (1) | PT2189537E (en) |
SI (1) | SI2189537T1 (en) |
WO (1) | WO2009025159A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143762A1 (en) * | 2009-06-12 | 2010-12-16 | (주)바이오니아 | Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011142460A1 (en) * | 2010-05-14 | 2011-11-17 | 財団法人東京都医学総合研究所 | Method for detecting schizophrenia |
CN102993191B (en) * | 2012-12-18 | 2015-05-27 | 苏州大学 | Heterocyclic chiral compound containing azlactone and pyrazolone, and derivative, synthetic method and use thereof |
WO2016031839A1 (en) | 2014-08-29 | 2016-03-03 | 株式会社プロジェクトPm | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound |
KR101796390B1 (en) * | 2015-07-24 | 2017-11-09 | 동국대학교 산학협력단 | Novel compound having BLT-inhibitory activity and composition for preventing or treating inflammatory diseases comprising the same as an active ingredient |
JP6105111B1 (en) | 2016-03-02 | 2017-03-29 | 国立大学法人東北大学 | Composition for improving autism spectrum disorder |
CN109982639A (en) * | 2017-07-07 | 2019-07-05 | 松下知识产权经营株式会社 | Information providing method, information processing system, information terminal and information processing method |
JP6643747B2 (en) * | 2017-07-07 | 2020-02-12 | パナソニックIpマネジメント株式会社 | Information providing method, information processing system, and information processing method |
JP6924964B2 (en) * | 2017-07-07 | 2021-08-25 | パナソニックIpマネジメント株式会社 | Information provision method, information processing system, information terminal, and information processing method |
US11932880B2 (en) | 2018-02-27 | 2024-03-19 | Kikkoman Corporation | Enzyme and method for assaying pentosidine using same |
WO2021039611A1 (en) * | 2019-08-27 | 2021-03-04 | キッコーマン株式会社 | Method for measuring pentosidine and measurement kit |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001245661A (en) | 2000-03-07 | 2001-09-11 | Univ Niigata | Objective diagnostic method for schizophrenia using gene expression as index |
JP2003038198A (en) | 2001-07-27 | 2003-02-12 | Univ Niigata | Method for analyzing nucleic acid specifying gene having expression level changeable with schizophrenia |
JP2003212795A (en) | 2002-01-15 | 2003-07-30 | Japan Science & Technology Corp | Diagnostic agent of schizophrenia |
WO2004005935A1 (en) | 2002-07-04 | 2004-01-15 | Mitsubishi Pharma Corporation | Method of examining and diagnosing integration dysfunction syndrome |
JP2004251865A (en) | 2003-02-19 | 2004-09-09 | Takashi Muramatsu | Drug for examining schizophrenia and alzheimer's disease |
JP2005055227A (en) | 2003-07-31 | 2005-03-03 | Japan Science & Technology Agency | Method for diagnosing integrated dystonia |
WO2005030737A1 (en) | 2003-09-30 | 2005-04-07 | Sankyo Company, Limited | Phenylene derivative having tetrazole ring or thiazolidinedione ring |
WO2005054205A1 (en) | 2003-12-05 | 2005-06-16 | Tokai University Educational System | Protein modifier production inhibitor |
JP2005278490A (en) | 2004-03-29 | 2005-10-13 | Japan Science & Technology Agency | Method for determining biological marker involving schizophrenia and utilization of the same |
WO2007026962A1 (en) | 2005-08-31 | 2007-03-08 | Daiichi Sankyo Company, Limited | Phenylene derivative |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52102431A (en) * | 1976-02-25 | 1977-08-27 | Kyowa Hakko Kogyo Co Ltd | Remedies for mental disorder |
CA2436522A1 (en) * | 2001-01-31 | 2002-08-08 | Katia Vancompernolle | Phosphorylated glyoxalase i and its use |
NL1019368C2 (en) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparation for improving receptor performance. |
US20050249823A1 (en) | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
US20100137635A1 (en) | 2005-06-07 | 2010-06-03 | Inbiotex Inc. | Radical scavenger and active oxygen eliminating agent |
-
2007
- 2007-08-20 JP JP2007214047A patent/JP5288365B2/en not_active Expired - Fee Related
-
2008
- 2008-07-31 WO PCT/JP2008/063803 patent/WO2009025159A1/en active Application Filing
- 2008-07-31 EP EP20130003496 patent/EP2662453A3/en not_active Withdrawn
- 2008-07-31 EP EP08792016.1A patent/EP2189537B1/en active Active
- 2008-07-31 ES ES08792016.1T patent/ES2515168T3/en active Active
- 2008-07-31 US US12/674,018 patent/US8809329B2/en active Active
- 2008-07-31 SI SI200831305T patent/SI2189537T1/en unknown
- 2008-07-31 DK DK08792016.1T patent/DK2189537T3/en active
- 2008-07-31 PL PL08792016T patent/PL2189537T3/en unknown
- 2008-07-31 PT PT87920161T patent/PT2189537E/en unknown
-
2014
- 2014-07-08 US US14/325,808 patent/US20140335517A1/en not_active Abandoned
- 2014-10-10 CY CY20141100824T patent/CY1115640T1/en unknown
- 2014-10-16 HR HRP20140993AT patent/HRP20140993T1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001245661A (en) | 2000-03-07 | 2001-09-11 | Univ Niigata | Objective diagnostic method for schizophrenia using gene expression as index |
JP2003038198A (en) | 2001-07-27 | 2003-02-12 | Univ Niigata | Method for analyzing nucleic acid specifying gene having expression level changeable with schizophrenia |
JP2003212795A (en) | 2002-01-15 | 2003-07-30 | Japan Science & Technology Corp | Diagnostic agent of schizophrenia |
WO2004005935A1 (en) | 2002-07-04 | 2004-01-15 | Mitsubishi Pharma Corporation | Method of examining and diagnosing integration dysfunction syndrome |
JP2004251865A (en) | 2003-02-19 | 2004-09-09 | Takashi Muramatsu | Drug for examining schizophrenia and alzheimer's disease |
JP2005055227A (en) | 2003-07-31 | 2005-03-03 | Japan Science & Technology Agency | Method for diagnosing integrated dystonia |
WO2005030737A1 (en) | 2003-09-30 | 2005-04-07 | Sankyo Company, Limited | Phenylene derivative having tetrazole ring or thiazolidinedione ring |
WO2005054205A1 (en) | 2003-12-05 | 2005-06-16 | Tokai University Educational System | Protein modifier production inhibitor |
JP2005278490A (en) | 2004-03-29 | 2005-10-13 | Japan Science & Technology Agency | Method for determining biological marker involving schizophrenia and utilization of the same |
WO2007026962A1 (en) | 2005-08-31 | 2007-03-08 | Daiichi Sankyo Company, Limited | Phenylene derivative |
Non-Patent Citations (46)
Title |
---|
"Diagnostic and Statistical Manual, Fourth Edition", AMERICAN PSYCHIATRIC ASSOCIATION |
"Polymerase Chain Reaction-Single Strand Conformation Polymorphism Analysis", BIOTECHNIQUES, vol. 16, 1994, pages 296 - 297 |
ANAL. CHEM., vol. 72, 2000, pages 1334 - 1341 |
BIOTECHNIQUES, vol. 11, 1991, pages 246 - 249 |
BIOTECHNIQUES, vol. 21, 1996, pages 216 - 218 |
BIOTECHNIQUES, vol. 21, 1996, pages 510 - 514 |
BIOTECHNIQUES, vol. 27, 1999, pages 1016 - 1018 |
BRUCE ET AL.: "Geneme Analysis/A Laboratory Manual", vol. 4, 1999, COLD SPRING HARBOR LABORATORY |
CLIN. CHIM. ACTA, vol. 189, 1990, pages 153 - 157 |
DNA CELL. BIOL., vol. 14, 1995, pages 87 - 94 |
EUR. J. CLIN. CHEM. CLIN. BIOCHEM., vol. 35, 1997, pages 545 - 548 |
GALE C.P. ET AL.: "Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors", DIAB.VASC.DIS.RES., vol. 1, no. 1, 2004, pages 34 - 39, XP008132143 * |
GENE & MEDICINE, vol. 4, 2000, pages 46 - 48 |
GENE & MEDICINE, vol. 4, 2000, pages 47 - 48 |
GENE & MEDICINE, vol. 4, 2000, pages 50 - 51 |
GENET. ANAL., vol. 14, 1999, pages 143 - 149 |
GENOME RES., vol. 7, 1997, pages 378 - 388 |
GENOME RES., vol. 8, 1998, pages 549 - 556 |
J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 - 2936 |
J.BIOL.CHEM., vol. 30, 1999, pages 21387 - 21394 |
KENICHI MATSUBARA; YOSHIKI SAKAKI: "Strategy for SNP genetic polymorphism", NALAYAMA-SHOTEN, pages: 128 - 135 |
LIVAK KJ, GENE ANAL, vol. 14, 1999, pages 143 |
LYAMICHEV V. ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 292 |
MCGLASHAN, SCHIZOPHR BULL, 1988 |
MCLELLAN AC: "Thornalley PJ: Glyoxalase activity in human red blood cells fractioned by age", MECH AGEING DEV, vol. 48, 1989, pages 63 - 71 |
MCLELLAN AC; THORNALLEY PJ: "Glyoxalase activity in human red blood cells fractioned by age", MECH AGEING DEV, vol. 48, 1989, pages 63 - 71 |
MIYATA T. ET AL.: "Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient", KIDNEY INT., vol. 60, no. 6, 2001, pages 2351 - 2359, XP002355559 * |
MIYATA, T ET AL., J. AM. SOC., NEPHROL., vol. 7, 1996, pages 1198 - 1206 |
MIYATA, T. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 2353 - 2358 |
MIYATA, T. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 93, 1996, pages 2353 - 2358 |
MORRIS T ET AL., J CLIN MICROBIOL, vol. 34, 1996, pages 2933 |
NAT. BIOTECHNOL., vol. 1, 1998, pages 49 - 53 |
NAT. BIOTECHNOL., vol. 1, 1999, pages 87 - 88 |
NAT. BIOTECHNOL., vol. 17, 1999, pages 292 - 296 |
NAT. GENET., vol. 3, 1998, pages 225 - 232 |
NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 303 - 308 |
NUC. ACIDS. RES., vol. 19, 1991, pages 3561 - 3567 |
NUC. ACIDS. RES., vol. 20, 1992, pages 4831 - 4837 |
POLITI P. ET AL.: "Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder", NEUROSCI.LETT., vol. 396, no. 2, 2006, pages 163 - 166, XP025023590 * |
PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 10756 - 10761 |
SACCO R. ET AL.: "Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1", BMC MED.GENET., vol. 8, no. 11, March 2007 (2007-03-01), pages 1 - 9, XP008132135 * |
SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOUR LABORATORY PRESS |
SAMBROOK J. ET AL.: "Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOR LABORATORY |
SCIENCE, vol. 5109, 1993, pages 778 - 783 |
See also references of EP2189537A4 |
TURNER W.J. ET AL.: "Genetic markers for schizotaxia", BIOL.PSYCHIATRY, vol. 14, no. 1, 1979, pages 177 - 206, XP008132140 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143762A1 (en) * | 2009-06-12 | 2010-12-16 | (주)바이오니아 | Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same |
US8551426B2 (en) | 2009-06-12 | 2013-10-08 | Bioneer Corporation | Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same |
Also Published As
Publication number | Publication date |
---|---|
US8809329B2 (en) | 2014-08-19 |
JP5288365B2 (en) | 2013-09-11 |
SI2189537T1 (en) | 2014-11-28 |
CY1115640T1 (en) | 2017-01-04 |
EP2662453A2 (en) | 2013-11-13 |
EP2662453A3 (en) | 2014-02-26 |
ES2515168T3 (en) | 2014-10-29 |
PT2189537E (en) | 2014-10-30 |
EP2189537A1 (en) | 2010-05-26 |
JP2009039088A (en) | 2009-02-26 |
DK2189537T3 (en) | 2014-10-27 |
US20140335517A1 (en) | 2014-11-13 |
EP2189537B1 (en) | 2014-10-08 |
US20110028470A1 (en) | 2011-02-03 |
HRP20140993T1 (en) | 2014-12-19 |
EP2189537A4 (en) | 2010-08-11 |
PL2189537T3 (en) | 2015-01-30 |
US20120065198A2 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009025159A1 (en) | Detection and treatment of schizophrenia | |
Zhou et al. | Transcriptomic and biochemical analysis of highlighted induction of phenylpropanoid pathway metabolism of citrus fruit in response to salicylic acid, Pichia membranaefaciens and oligochitosan | |
Daines et al. | First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling | |
Seyedsayamdost et al. | Mixing and matching siderophore clusters: structure and biosynthesis of serratiochelins from Serratia sp. V4 | |
WO2009048072A1 (en) | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 | |
WO2008062276A8 (en) | Acetylene derivatives as stearoyl coa desaturase inhibitors | |
WO2010046445A3 (en) | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | |
NO20092723L (en) | Indazolyl esters and amide derivatives for the treatment of glucocorticoid receptor-mediated diseases | |
WO2009100872A8 (en) | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | |
MX2008014101A (en) | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments. | |
WO2010001169A3 (en) | Chemical compounds 251 | |
WO2005092877A8 (en) | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof | |
HK1133596A1 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
EP2020445A4 (en) | Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease | |
GEP20125511B (en) | Mapk/erk kinase inhibitors | |
WO2007140005A3 (en) | Oxazolyl piperidine modulators of fatty acid amide hydrolase | |
TW200745136A (en) | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives | |
WO2008024139A3 (en) | Inhibitors of fatty acid amide hydrolase | |
WO2008027162A3 (en) | 129xe biosensors and their use | |
CA2874960C (en) | Euglobulin-based method for determining the biological activity of defibrotide | |
MX2008011175A (en) | Phosphodiesterase 10 inhibitors. | |
WO2008106594A3 (en) | Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis | |
UA86441C2 (en) | (2-hydroxyethyl)trimethylammonium thiooctate (choline thioctate), having hepatoprotective, hypoamoniemic and detoxic action, method for production thereof and pharmaceutical compositions based on it | |
Pan et al. | Synthesis of 4′-thiosemicarbazonegriseofulvin and its effects on the control of enzymatic browning and postharvest disease of fruits | |
WO2008081094A3 (en) | Method for the functional measurement of plasmatic thromboduline activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08792016 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12674018 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008792016 Country of ref document: EP |